Alzheimer's Disease

Cyclo Therapeutics announced that a phase 2b study for its investigational drug Trappsol Cyclo, which targets the reduction of amyloid beta and tau in the treatment of early Alzheimer’s disease, is now underway.

In this edition, lecanemab study shows reduction in clinical decline for early AD; multimorbidity associated with increased risk for dementia, Crenezumab not effective in treating Alzheimer's disease and more.

Treatment with sildenafil or tadalafil was not associated with a reduced risk for incident Alzheimer’s disease and related dementia in patients with pulmonary hypertension, according to a study published in Brain Communications.

Alzamend Neuro has submitted an investigational new drug application to the FDA for its Alzheimer’s immunotherapeutic product, ALZN002, according to a company press release.

Corium Inc. announced that Adlarity transdermal treatment is available to prescribe in the U.S. for patients with Alzheimer’s.

SAN DIEGO – One compound from Annovis Bio is showing success in phase 2 clinical trials for both Alzheimer’s disease and Parkinsons’ disease, a company executive said at the Alzheimer’s Association International Conference.

Researchers identified a correlation between eGFR and urine albumin-creatinine ratio with structural brain damage across various regions of etiology, according to data published in the American Journal of Kidney Diseases.

LAS VEGAS — To slow or stave off symptoms relating to Alzheimer’s disease and dementia, individuals should make healthy habits a priority early in life, according to a presenter at BRAINWeek 2022.

Pharmaceutical companies Biogen and Eisai announced results from a phase 3 trial that demonstrated treatment with lecanemab reduced cognitive decline by 27% after 18 months compared with placebo.

Although it was well tolerated, the anti-amyloid antibody crenezumab did not reduce clinical decline in patients with Alzheimer's disease, researchers reported in JAMA Neurology.